RxDoctor Payments Data

Barton Billeci, MD

Adolescent Medicine · Irvine, CANPI 1154407237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 49.6% of the total. Reporting peaked in 2019 at $303 and has fallen 94.1% since, to $18 in 2023.

$770in general payments, 2019–2025

Across 51 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$382
  • Novo Nordisk$187
  • Eisai Inc.$56
  • Johnson & Johnson$37
  • Pfizer$26
  • AbbVie$24
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$76499%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$770 in reported general payments places this provider in the 70th percentile of 202 adolescent medicine providers in California.

See all adolescent medicine providers in California

Medicare billing

Part B allowed, 2024
$27,712
Medicare patients
127
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol24$32,496
OzempicSemaglutide22$26,399
JardianceEmpagliflozin12$20,304
Olmesartan Medoxomil59$1,130
SynthroidLevothyroxine Sodium15$1,046
Eszopiclone39$998
Metformin Hcl ErMetformin Hcl75$942
Amlodipine Besylate157$891
Atorvastatin Calcium107$879
Gabapentin35$835
Escitalopram Oxalate60$830
Losartan Potassium116$812
Rosuvastatin Calcium90$782
Potassium Chloride23$767
Albuterol Sulfate HfaAlbuterol Sulfate38$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$382$32,49624 claims
Novo NordiskOzempic$187$26,39922 claims
AbbVieSynthroid$24$1,04615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 202 adolescent medicine providers in California.

Other adolescent medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →